Weight loss drugs may offer a new avenue for bipolar disorder research

Recent research from Griffith University suggests that weight loss drugs, specifically a class known as GLP-1 receptor agonists, could offer new mental health benefits, particularly for individuals with bipolar disorder. Diabetes, obesity, and bipolar disorder often co-occur and may share underlying mechanisms. The World Health Organization estimates that 37 million people, or roughly 1 in 200 globally, live with bipolar disorder.

While these medications are commonly used to treat diabetes and obesity, their potential impact on bipolar disorder has yet to be fully understood. A large study led by Professor Mark Taylor from Griffith University's School of Medicine and Dentistry analyzed data from nearly 15,000 individuals with bipolar disorder who were prescribed GLP-1 medications over a span of 15 years.

The findings, published in the journal Acta Psychiatrica Scandinavica, indicate that people taking semaglutide, a type of GLP-1 medication, experienced significantly lower rates of psychiatric hospitalization compared to periods when they were not taking the drug. Semaglutide was associated with a 21% reduced risk of psychiatric hospitalization, implying that GLP-1 receptor agonists may have benefits beyond their primary uses.

The study suggests that GLP-1 signaling may protect the brain by reducing inflammation, cellular stress, and other processes linked to bipolar disorder, potentially improving mood stability and reducing the risk of relapse. However, the researchers found no similar association with other GLP-1 medications like liraglutide and dulaglutide, indicating that the protective effect may not be universal across all GLP-1 drugs.

While these results are promising, the researchers emphasize the need for further testing in randomized controlled trials to confirm causality and mechanisms.